**Oxytocin Special interest Group (OxytocinSIG)**

**Meeting Minutes**

**Date & Time:** Thursday, May 19, 2022 at 9 am EST

**Attendees:**

|  |  |  |
| --- | --- | --- |
| Present | Country | Name |
| X | Canada | Sally Pepper |
| X | Canada | Dorothy Tscheng |
| X | Canada | David U |
| X | Canada | Alice Watt |
| X | Colombia | Ismael Basto Benitez |
| X | France | Etienne Schmitt |
|  | Germany | Günter Emons |
|  | Germany | Wolfgang Paulus |
| X | Germany | Birgit Vogt |
| X | Ireland | Peter Duddy |
| X | Netherlands | Thijs Ambagts |
|  | Qatar | Wessam Elkassem |
| X | Saudi Arabia | Hind Almodaimegh |
| X | Singapore | Cynthia Leow |
|  | United Kingdom | Donald Peebles |
|  | United Kingdom | Sascha Wells-Munro |
| X | USA | Mike Cohen |
| X | USA | Rita Jew |
| X | USA | Michelle Mandrack |
| X | USA | Chris Michalek |
|  | USA | Sunny Ro |
|  | Health Canada | Parag Buch |
| X | ISoP | Brian Edwards |
| X | UK NHS | Sharon Murrell |
|  | WHO | Alpana Mair |
|  | WHO | Fumihito Takanashi |

Guest: Logan Moore

|  |  |  |  |
| --- | --- | --- | --- |
| **Topic** | **Presenter** | **Discussion** | **Action Items** |
| Introduction | Rita Jew | Guest presenter was introduced |  |
| Approval of Charter | Rita Jew | There were no edits or comments on the Charter | Charter was approved |
| ISMP Canada presentation | Alice Watt | 178 oxytocin errors were reported to ISMP Canada, 12% resulted in neonatal or maternal harm and most errors occurred during drug administration. Main issues identified included preparation & labeling problems, no premixed standardized oxytocin, lack of safe storage measures, IV admin (confusion of lines) and communications.  Presentation centered around initiatives to empower patients and caregivers to ask questions regarding use of oxytocin. It included a review of a safety initiative to implement the “5 Questions to Ask” regarding oxytocin use in advanced labor.  Question: How was the data obtained and was this through voluntary event reporting?   * Alice Watt responded that data was obtained through collaboration with ISMP Canada and government agencies, with reports coming from voluntary reporting.   Question: Are there premixed preparations of oxytocin available in Canada?   * Alice Watt responded that they are being compounded by outside facilities.   Question: Have there been reports for use outside the hospital setting for instance when labor/delivery care is delivered at home? Is this data being captured?   * Alice Watt responded that the data is mostly centered around use in the hospital setting.   Question: Do these events include oxytocin use with postpartum bleeding?   * Alice Watt responded that this initiative focused on labor and delivery, but future projects and directions could look into postpartum bleeding and safety recommendations for that indication. | None |
| ISMP USA presentation | Logan Moore | Background information regarding oxytocin’s indications for use and precautions was presented. 2 errors were reported to ISMP US between 1999 and 2019. Most of the errors originated from dispensing, followed by administration and prescribing. 25% of the events resulted in maternal, fetal or neonatal harm. Five event themes included prescribing errors, look-alike drug packaging and names, preparation challenges, administration errors and communications.    Presentation focused on the ISMP Targeted Medication Safety Best Practices 2022-2023 recommendations for oxytocin.  Question: What is the rational for recommendation #5 “Avoid bringing oxytocin infusion bags to the patient’s bedside until prescribed & needed”.   * Chris Michalek responded by stating a couple of examples of concern if oxytocin is at the bedside without it being used immediately included: potential confusion with other fluid products as observed in error reports and the potential that oxytocin could be given at the wrong time if already in the room without an active order. | None |
| Next steps | Rita Jew | Possible round-robin discussion on member’s experiences | Rita asked members who would like to present at the next meeting to contact her or David U. |
| Respectfully submitted: Logan Moore & Rita Jew | | | |